June 25, 2021. The Court in the Insulet securities matter
(District Court of Massachusetts) approved a class action settlement in the
amount of $19.5 million. Plaintiffs alleged that the company misled investors
about the success of its new insulin infusion system, the system’s patient
adoption and growth rates, and associated financial projections. Professor Steven Feinstein of Babson College and Crowninshield
Financial Research provided an expert report on market efficiency and consulted
on the computation of damages.
Read more on this case at Stanford Securities Class Action Clearinghouse.